Mar 31, 2020
AbbVie Donates $35 Million for COVID-19 Relief to Support Healthcare Systems, Patients and Communities
Mar 30, 2020
Synlogic Provides Summary of Impact of COVID-19 on Clinical Program Progress and Operational Activities
Mar 30, 2020
AbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director
Mar 23, 2020
AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes
Mar 23, 2020
AbbVie Announces Positive Topline Results from Phase 3 Trial of VENCLEXTA® (venetoclax) in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)
Mar 18, 2020
Allergan Declares Second Quarter 2020 Cash Dividend of $0.74 Per Ordinary Share
Mar 17, 2020
AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction
Mar 16, 2020
Preclinical Stage Partnering Deals in Pharma & Biotech, 2014-2020 - Access to 1,400+ Deal Records; Leading Deals by Value, Most Active Dealmakers
Mar 12, 2020
Synlogic Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Mar 11, 2020
Synlogic to Present at Chardan's Virtual Microbiome Medicines Summit
Mar 11, 2020
Clinical Stage Partnering Deals in Pharma & Biotech, 2014-2020 - Access to Over 2,000 Global Clinical Stage Deals
Mar 11, 2020
Big Pharma Partnering Terms & Agreements, Worldwide, 2014-2020 - Deal Trends, Key Players, Top Deal Values, Deal Financials
Mar 09, 2020
AbbVie Partnering with Global Authorities to Determine Efficacy of HIV Drug in Treating COVID-19
Mar 09, 2020
AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes
Mar 05, 2020
Synlogic Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast
Mar 03, 2020
AbbVie and Allergan Receive Final European Approval to Close Pending Transaction
Feb 28, 2020
AbbVie Provides Update from Phase 3 Study Evaluating VENCLEXTA® (venetoclax) in Combination with Low-Dose Cytarabine in Newly-Diagnosed Patients with Acute Myeloid Leukemia (AML)
Feb 28, 2020
AbbVie Provides Update from Phase 3 Study Evaluating VENCLEXTA® (venetoclax) in Combination with Low-Dose Cytarabine in Newly-Diagnosed Patients with Acute Myeloid Leukemia (AML)
Feb 25, 2020
AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue
Feb 24, 2020
Halozyme Reports Fourth Quarter and Full Year 2019 Results